We report a preliminary pilot study on the clinical efficacy of flunar
izine (FNZ), a calcium-entry blocker that causes extrapyramidal side-e
ffects, in 10 patients with Huntington's disease (HD). FNZ (20 mg) adm
inistered by the sublingual route resulted in a decrease in choreic mo
vements and improved dexterity in performing several tests. These effe
cts lasted for at least 7 days after a single dose. Therefore, FNZ see
ms to exert the same effect as a long-acting neuroleptic agent in our
HD patients. (C) 1998 Lippincott-Raven Publishers.